Article
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.
The EMBO journal - 15 Oct 2019
Timofeev Oleg, Klimovich Boris, Schneikert Jean, Wanzel Michael, Pavlakis Evangelos, Noll Julia, Mutlu Samet, Elmshäuser Sabrina, Nist Andrea, Mernberger Marco, Lamp Boris, Wenig Ulrich, Brobeil Alexander, Gattenlöhner Stefan, Köhler Kernt, Stiewe Thorsten
Abstract excerpt
Engineered p53 mutant mice are valuable tools for delineating p53 functions in tumor suppression and cancer therapy. Here, we have introduced the R178E mutation into the Trp53 gene of mice to specifically ablate the cooperative nature of p53 DNA binding. Trp53R178E mice show no detectable target gene regulation and, at first sight, are largely indistinguishable from Trp53-/- mice. Surprisingly, stabilization of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.